Sorbonne Université and INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, 27 rue Chaligny 75571 Paris CEDEX 12, France; L'Institut Desbrest d'Épidémiologie et de Santé Publique (IDESP), INSERM & University of Montpellier, IURC, 641, Avenue du Doyen Gaston Giraud, 34093, Montpellier, France; Department of Community Medicine, Chandka Medical College, SMBB Medical University, Larkana, Pakistan.
Sorbonne Université and INSERM, Pierre Louis Institute of Epidemiology and Public Health (IPLESP UMRS 1136), Epidemiology of Allergic and Respiratory Diseases Department (EPAR), Saint-Antoine Medical School, 27 rue Chaligny 75571 Paris CEDEX 12, France.
J Gynecol Obstet Hum Reprod. 2021 Dec;50(10):102216. doi: 10.1016/j.jogoh.2021.102216. Epub 2021 Sep 2.
Studies have suggested that exposure to endocrine disruptors such as phthalates that are widely used in our daily life (food wrapping, cosmetics, toys, medical devices, polyvinyl chloride flooring, and building materials) might be related to raised blood pressure and increased risk of cardiovascular diseases. Phthalates might induce a pro-inflammatory response and increased oxidative stress and may be a cause of pregnancy induced hypertension.
We evaluated the association between maternal exposure to phthalates during pregnancy and pregnancy induced hypertension. 604 pregnant women were included and eleven phthalate metabolites were quantified in spot maternal urine samples collected between the 23rd and 28th week of gestation in a French EDEN mother-child cohort. The associations were assessed by applying multiple logistic regression analysis.
Twenty nine (4,8%) mothers developed pregnancy induced hypertension. Two low molecular weight phthalate metabolites: Monoethyl phthalate (MEP) and Mono-n‑butyl phthalate (MBP) were positively associated with pregnancy induced hypertension in crude (Odds Ratio: 1.43, 95% Confidence Interval: 1.04-1.96, p-value = 0.02 and 1.48, 1.10-2.01, p-value =0.01) and in adjusted (1.47, 1.01-2.14, p-value = 0.04 and 1.66, 1.11-2.47, p-value = 0.01) models respectively.
Our data suggest that prenatal exposure to some phthalates, including MEP and MBP, might play a role in pregnancy induced hypertension.
研究表明，日常生活中广泛使用的内分泌干扰物（如邻苯二甲酸酯）的暴露，可能与血压升高和心血管疾病风险增加有关。邻苯二甲酸酯可能会引起炎症反应和氧化应激增加，并且可能是妊娠高血压的原因。
我们评估了孕妇在怀孕期间接触邻苯二甲酸酯与妊娠高血压之间的关系。在法国 EDEN 母婴队列中，纳入了 604 名孕妇，并在妊娠 23 至 28 周期间收集了点样孕妇尿液样本，共检测了 11 种邻苯二甲酸酯代谢物。通过应用多变量逻辑回归分析评估了相关性。
29 名（4.8%）母亲发生妊娠高血压。两种低分子量邻苯二甲酸酯代谢物：邻苯二甲酸单乙酯（MEP）和邻苯二甲酸单丁酯（MBP）在未调整和调整模型中均与妊娠高血压呈正相关（比值比：1.43，95%置信区间：1.04-1.96，p 值=0.02 和 1.48，1.10-2.01，p 值=0.01）。
我们的数据表明，产前接触某些邻苯二甲酸酯，包括 MEP 和 MBP，可能在妊娠高血压中发挥作用。
